Loading…

Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath

Human breath offers several benefits for diagnostic applications, including simple, noninvasive collection. Breath is a rich source of clinically-relevant biological information; this includes a volatile fraction, where greater than 1,000 volatile organic compounds (VOCs) have been described so far,...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in clinical laboratory sciences 2022-07, Vol.59 (5), p.353-372
Main Authors: Haworth, Jordan J., Pitcher, Charlotte K., Ferrandino, Giuseppe, Hobson, Anthony R., Pappan, Kirk L., Lawson, Jonathan L. D.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83
cites cdi_FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83
container_end_page 372
container_issue 5
container_start_page 353
container_title Critical reviews in clinical laboratory sciences
container_volume 59
creator Haworth, Jordan J.
Pitcher, Charlotte K.
Ferrandino, Giuseppe
Hobson, Anthony R.
Pappan, Kirk L.
Lawson, Jonathan L. D.
description Human breath offers several benefits for diagnostic applications, including simple, noninvasive collection. Breath is a rich source of clinically-relevant biological information; this includes a volatile fraction, where greater than 1,000 volatile organic compounds (VOCs) have been described so far, and breath aerosols that carry nucleic acids, proteins, signaling molecules, and pathogens. Many of these factors, especially VOCs, are delivered to the lung by the systemic circulation, and diffusion of candidate biomarkers from blood into breath allows systematic profiling of organismal health. Biomarkers on breath offer the capability to advance early detection and precision medicine in areas of global clinical need. Breath tests are noninvasive and can be performed at home or in a primary care setting, which makes them well-suited for the kind of public screening program that could dramatically improve the early detection of conditions such as lung cancer. Since measurements of VOCs on breath largely report on metabolic changes, this too aids in the early detection of a broader range of illnesses and can be used to detect metabolic shifts that could be targeted through precision medicine. Furthermore, the ability to perform frequent sampling has envisioned applications in monitoring treatment responses. Breath has been investigated in respiratory, liver, gut, and neurological diseases and in contexts as diverse as infectious diseases and cancer. Preclinical research studies using breath have been ongoing for some time, yet only a few breath-based diagnostics tests are currently available and in widespread clinical use. Most recently, tests assessing the gut microbiome using hydrogen and methane on breath, in addition to tests using urea to detect Helicobacter pylori infections have been released, yet there are many more applications of breath tests still to be realized. Here, we discuss the strengths of breath as a clinical sampling matrix and the technical challenges to be addressed in developing it for clinical use. Historically, a lack of standardized methodologies has delayed the discovery and validation of biomarker candidates, resulting in a proliferation of early-stage pilot studies. We will explore how advancements in breath collection and analysis are in the process of driving renewed progress in the field, particularly in the context of gastrointestinal and chronic liver disease. Finally, we will provide a forward-looking outlook for developing th
doi_str_mv 10.1080/10408363.2022.2038075
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_35188863</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3087520574</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83</originalsourceid><addsrcrecordid>eNp9kclOHDEQhi0UFJbkEYgs5cKlwUvbXcOJRSGJhMSFSLlZHi_E4LYndg-It487M-TAIReXrfqq6nf9CB1RckIJkFNKegJc8hNGGGsHBzKIHbRPRb_oBqA_37V7Y7oZ2kMHtT4QQqRg_Xu0xwUFAMn3UbgsTk-_QrrHyT3jGLzDIU0ZmxhSMDriydVpTutksQ36PuX2NvUMr1ypK2em8OQqzgk_5ainEB1ehjzq8tjS2Jc84uXfER_Qrtexuo_beIh-XH-5u_rW3dx-_X51cdOZvqdTZ9hCM2mt98yCl5Iw1wOjhhiQBsxgvOXghXPeWiG0t9ADHZbOEMoGpoEfouNN31XJv9dNvBpDNS5GnVxeV8UkpyDFAmb08xv0Ia9LauoUJzAIRsTQN0psKFNyrcV5tSqhffBFUaJmL9SrF2r2Qm29aHWftt3Xy9HZf1Wvy2_A-QYIyecy6udcolWTfom5-KKTCU3H_2f8Ae1jmgc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3087520574</pqid></control><display><type>article</type><title>Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Haworth, Jordan J. ; Pitcher, Charlotte K. ; Ferrandino, Giuseppe ; Hobson, Anthony R. ; Pappan, Kirk L. ; Lawson, Jonathan L. D.</creator><creatorcontrib>Haworth, Jordan J. ; Pitcher, Charlotte K. ; Ferrandino, Giuseppe ; Hobson, Anthony R. ; Pappan, Kirk L. ; Lawson, Jonathan L. D.</creatorcontrib><description>Human breath offers several benefits for diagnostic applications, including simple, noninvasive collection. Breath is a rich source of clinically-relevant biological information; this includes a volatile fraction, where greater than 1,000 volatile organic compounds (VOCs) have been described so far, and breath aerosols that carry nucleic acids, proteins, signaling molecules, and pathogens. Many of these factors, especially VOCs, are delivered to the lung by the systemic circulation, and diffusion of candidate biomarkers from blood into breath allows systematic profiling of organismal health. Biomarkers on breath offer the capability to advance early detection and precision medicine in areas of global clinical need. Breath tests are noninvasive and can be performed at home or in a primary care setting, which makes them well-suited for the kind of public screening program that could dramatically improve the early detection of conditions such as lung cancer. Since measurements of VOCs on breath largely report on metabolic changes, this too aids in the early detection of a broader range of illnesses and can be used to detect metabolic shifts that could be targeted through precision medicine. Furthermore, the ability to perform frequent sampling has envisioned applications in monitoring treatment responses. Breath has been investigated in respiratory, liver, gut, and neurological diseases and in contexts as diverse as infectious diseases and cancer. Preclinical research studies using breath have been ongoing for some time, yet only a few breath-based diagnostics tests are currently available and in widespread clinical use. Most recently, tests assessing the gut microbiome using hydrogen and methane on breath, in addition to tests using urea to detect Helicobacter pylori infections have been released, yet there are many more applications of breath tests still to be realized. Here, we discuss the strengths of breath as a clinical sampling matrix and the technical challenges to be addressed in developing it for clinical use. Historically, a lack of standardized methodologies has delayed the discovery and validation of biomarker candidates, resulting in a proliferation of early-stage pilot studies. We will explore how advancements in breath collection and analysis are in the process of driving renewed progress in the field, particularly in the context of gastrointestinal and chronic liver disease. Finally, we will provide a forward-looking outlook for developing the next generation of clinically relevant breath tests and how they may emerge into clinical practice.</description><identifier>ISSN: 1040-8363</identifier><identifier>EISSN: 1549-781X</identifier><identifier>DOI: 10.1080/10408363.2022.2038075</identifier><identifier>PMID: 35188863</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Biomarkers ; Breath ; Breath tests ; early detection ; Metabolism ; noninvasive ; Precision medicine ; VOCs ; Volatile organic compounds</subject><ispartof>Critical reviews in clinical laboratory sciences, 2022-07, Vol.59 (5), p.353-372</ispartof><rights>2022 Owlstone Medical Ltd. Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2022</rights><rights>2022 Owlstone Medical Ltd. Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution – Non-Commercial – No Derivatives License http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83</citedby><cites>FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83</cites><orcidid>0000-0003-2305-2906 ; 0000-0002-2341-8798 ; 0000-0002-1981-8641 ; 0000-0003-2331-2157 ; 0000-0002-5325-0789 ; 0000-0003-1609-8455</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35188863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Haworth, Jordan J.</creatorcontrib><creatorcontrib>Pitcher, Charlotte K.</creatorcontrib><creatorcontrib>Ferrandino, Giuseppe</creatorcontrib><creatorcontrib>Hobson, Anthony R.</creatorcontrib><creatorcontrib>Pappan, Kirk L.</creatorcontrib><creatorcontrib>Lawson, Jonathan L. D.</creatorcontrib><title>Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath</title><title>Critical reviews in clinical laboratory sciences</title><addtitle>Crit Rev Clin Lab Sci</addtitle><description>Human breath offers several benefits for diagnostic applications, including simple, noninvasive collection. Breath is a rich source of clinically-relevant biological information; this includes a volatile fraction, where greater than 1,000 volatile organic compounds (VOCs) have been described so far, and breath aerosols that carry nucleic acids, proteins, signaling molecules, and pathogens. Many of these factors, especially VOCs, are delivered to the lung by the systemic circulation, and diffusion of candidate biomarkers from blood into breath allows systematic profiling of organismal health. Biomarkers on breath offer the capability to advance early detection and precision medicine in areas of global clinical need. Breath tests are noninvasive and can be performed at home or in a primary care setting, which makes them well-suited for the kind of public screening program that could dramatically improve the early detection of conditions such as lung cancer. Since measurements of VOCs on breath largely report on metabolic changes, this too aids in the early detection of a broader range of illnesses and can be used to detect metabolic shifts that could be targeted through precision medicine. Furthermore, the ability to perform frequent sampling has envisioned applications in monitoring treatment responses. Breath has been investigated in respiratory, liver, gut, and neurological diseases and in contexts as diverse as infectious diseases and cancer. Preclinical research studies using breath have been ongoing for some time, yet only a few breath-based diagnostics tests are currently available and in widespread clinical use. Most recently, tests assessing the gut microbiome using hydrogen and methane on breath, in addition to tests using urea to detect Helicobacter pylori infections have been released, yet there are many more applications of breath tests still to be realized. Here, we discuss the strengths of breath as a clinical sampling matrix and the technical challenges to be addressed in developing it for clinical use. Historically, a lack of standardized methodologies has delayed the discovery and validation of biomarker candidates, resulting in a proliferation of early-stage pilot studies. We will explore how advancements in breath collection and analysis are in the process of driving renewed progress in the field, particularly in the context of gastrointestinal and chronic liver disease. Finally, we will provide a forward-looking outlook for developing the next generation of clinically relevant breath tests and how they may emerge into clinical practice.</description><subject>Biomarkers</subject><subject>Breath</subject><subject>Breath tests</subject><subject>early detection</subject><subject>Metabolism</subject><subject>noninvasive</subject><subject>Precision medicine</subject><subject>VOCs</subject><subject>Volatile organic compounds</subject><issn>1040-8363</issn><issn>1549-781X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><recordid>eNp9kclOHDEQhi0UFJbkEYgs5cKlwUvbXcOJRSGJhMSFSLlZHi_E4LYndg-It487M-TAIReXrfqq6nf9CB1RckIJkFNKegJc8hNGGGsHBzKIHbRPRb_oBqA_37V7Y7oZ2kMHtT4QQqRg_Xu0xwUFAMn3UbgsTk-_QrrHyT3jGLzDIU0ZmxhSMDriydVpTutksQ36PuX2NvUMr1ypK2em8OQqzgk_5ainEB1ehjzq8tjS2Jc84uXfER_Qrtexuo_beIh-XH-5u_rW3dx-_X51cdOZvqdTZ9hCM2mt98yCl5Iw1wOjhhiQBsxgvOXghXPeWiG0t9ADHZbOEMoGpoEfouNN31XJv9dNvBpDNS5GnVxeV8UkpyDFAmb08xv0Ia9LauoUJzAIRsTQN0psKFNyrcV5tSqhffBFUaJmL9SrF2r2Qm29aHWftt3Xy9HZf1Wvy2_A-QYIyecy6udcolWTfom5-KKTCU3H_2f8Ae1jmgc</recordid><startdate>20220704</startdate><enddate>20220704</enddate><creator>Haworth, Jordan J.</creator><creator>Pitcher, Charlotte K.</creator><creator>Ferrandino, Giuseppe</creator><creator>Hobson, Anthony R.</creator><creator>Pappan, Kirk L.</creator><creator>Lawson, Jonathan L. D.</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><scope>0YH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2305-2906</orcidid><orcidid>https://orcid.org/0000-0002-2341-8798</orcidid><orcidid>https://orcid.org/0000-0002-1981-8641</orcidid><orcidid>https://orcid.org/0000-0003-2331-2157</orcidid><orcidid>https://orcid.org/0000-0002-5325-0789</orcidid><orcidid>https://orcid.org/0000-0003-1609-8455</orcidid></search><sort><creationdate>20220704</creationdate><title>Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath</title><author>Haworth, Jordan J. ; Pitcher, Charlotte K. ; Ferrandino, Giuseppe ; Hobson, Anthony R. ; Pappan, Kirk L. ; Lawson, Jonathan L. D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Breath</topic><topic>Breath tests</topic><topic>early detection</topic><topic>Metabolism</topic><topic>noninvasive</topic><topic>Precision medicine</topic><topic>VOCs</topic><topic>Volatile organic compounds</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Haworth, Jordan J.</creatorcontrib><creatorcontrib>Pitcher, Charlotte K.</creatorcontrib><creatorcontrib>Ferrandino, Giuseppe</creatorcontrib><creatorcontrib>Hobson, Anthony R.</creatorcontrib><creatorcontrib>Pappan, Kirk L.</creatorcontrib><creatorcontrib>Lawson, Jonathan L. D.</creatorcontrib><collection>Taylor &amp; Francis</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in clinical laboratory sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Haworth, Jordan J.</au><au>Pitcher, Charlotte K.</au><au>Ferrandino, Giuseppe</au><au>Hobson, Anthony R.</au><au>Pappan, Kirk L.</au><au>Lawson, Jonathan L. D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath</atitle><jtitle>Critical reviews in clinical laboratory sciences</jtitle><addtitle>Crit Rev Clin Lab Sci</addtitle><date>2022-07-04</date><risdate>2022</risdate><volume>59</volume><issue>5</issue><spage>353</spage><epage>372</epage><pages>353-372</pages><issn>1040-8363</issn><eissn>1549-781X</eissn><abstract>Human breath offers several benefits for diagnostic applications, including simple, noninvasive collection. Breath is a rich source of clinically-relevant biological information; this includes a volatile fraction, where greater than 1,000 volatile organic compounds (VOCs) have been described so far, and breath aerosols that carry nucleic acids, proteins, signaling molecules, and pathogens. Many of these factors, especially VOCs, are delivered to the lung by the systemic circulation, and diffusion of candidate biomarkers from blood into breath allows systematic profiling of organismal health. Biomarkers on breath offer the capability to advance early detection and precision medicine in areas of global clinical need. Breath tests are noninvasive and can be performed at home or in a primary care setting, which makes them well-suited for the kind of public screening program that could dramatically improve the early detection of conditions such as lung cancer. Since measurements of VOCs on breath largely report on metabolic changes, this too aids in the early detection of a broader range of illnesses and can be used to detect metabolic shifts that could be targeted through precision medicine. Furthermore, the ability to perform frequent sampling has envisioned applications in monitoring treatment responses. Breath has been investigated in respiratory, liver, gut, and neurological diseases and in contexts as diverse as infectious diseases and cancer. Preclinical research studies using breath have been ongoing for some time, yet only a few breath-based diagnostics tests are currently available and in widespread clinical use. Most recently, tests assessing the gut microbiome using hydrogen and methane on breath, in addition to tests using urea to detect Helicobacter pylori infections have been released, yet there are many more applications of breath tests still to be realized. Here, we discuss the strengths of breath as a clinical sampling matrix and the technical challenges to be addressed in developing it for clinical use. Historically, a lack of standardized methodologies has delayed the discovery and validation of biomarker candidates, resulting in a proliferation of early-stage pilot studies. We will explore how advancements in breath collection and analysis are in the process of driving renewed progress in the field, particularly in the context of gastrointestinal and chronic liver disease. Finally, we will provide a forward-looking outlook for developing the next generation of clinically relevant breath tests and how they may emerge into clinical practice.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>35188863</pmid><doi>10.1080/10408363.2022.2038075</doi><tpages>20</tpages><orcidid>https://orcid.org/0000-0003-2305-2906</orcidid><orcidid>https://orcid.org/0000-0002-2341-8798</orcidid><orcidid>https://orcid.org/0000-0002-1981-8641</orcidid><orcidid>https://orcid.org/0000-0003-2331-2157</orcidid><orcidid>https://orcid.org/0000-0002-5325-0789</orcidid><orcidid>https://orcid.org/0000-0003-1609-8455</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1040-8363
ispartof Critical reviews in clinical laboratory sciences, 2022-07, Vol.59 (5), p.353-372
issn 1040-8363
1549-781X
language eng
recordid cdi_pubmed_primary_35188863
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects Biomarkers
Breath
Breath tests
early detection
Metabolism
noninvasive
Precision medicine
VOCs
Volatile organic compounds
title Breathing new life into clinical testing and diagnostics: perspectives on volatile biomarkers from breath
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T11%3A06%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Breathing%20new%20life%20into%20clinical%20testing%20and%20diagnostics:%20perspectives%20on%20volatile%20biomarkers%20from%20breath&rft.jtitle=Critical%20reviews%20in%20clinical%20laboratory%20sciences&rft.au=Haworth,%20Jordan%20J.&rft.date=2022-07-04&rft.volume=59&rft.issue=5&rft.spage=353&rft.epage=372&rft.pages=353-372&rft.issn=1040-8363&rft.eissn=1549-781X&rft_id=info:doi/10.1080/10408363.2022.2038075&rft_dat=%3Cproquest_pubme%3E3087520574%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c441t-c29a26ddff2d8f6602e4821c0c86c8c7cfd38f5eefdd55afd84817bec01272a83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3087520574&rft_id=info:pmid/35188863&rfr_iscdi=true